Unit
Brustzentrum St.Gallen
BZ · Dept. IV
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)
Rochlitz C, Zaman K, Mayer M, Cliffe B, Herrmann R, Mannhart-Harms M, Muller A, Rauch D, Winterhalder R, von Moos R, Schonenberger A, Fehr M, Bühlmann M, Suter T, Huober J, Spirig C, Lerch S, Ruhstaller T, Swiss Group for Clinical Cancer Research (SAKK). Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Ann Oncol 2010; 22:80-5.
Jul 1, 2010Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)
Jul 1, 2010Ann Oncol 2010; 22:80-5
Rochlitz C, Zaman K, Mayer M, Cliffe B, Herrmann R, Mannhart-Harms M, Muller A, Rauch D, Winterhalder R, von Moos R, Schonenberger A, Fehr M, Bühlmann M, Suter T, Huober Jens, Spirig C, Lerch S, Ruhstaller Thomas, Swiss Group for Clinical Cancer Research (SAKK)
Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?
Jörger M, Thürlimann B, Huober J. Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?. Ann Oncol 2010; 22:17-23.
Jun 20, 2010Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?
Jun 20, 2010Ann Oncol 2010; 22:17-23
Jörger Markus, Thürlimann Beat, Huober Jens
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study
Moebus V, Konecny G, Kreienberg R, Hinke A, Runnebaum I, von Minckwitz G, Harbeck N, Huober J, Schneeweiss A, Nitz U, Kuhn W, Kurbacher C, Thomssen C, du Bois A, Lueck H, Jackisch C, Untch M. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 2010; 28:2874-80.
Jun 10, 2010Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study
Jun 10, 2010J Clin Oncol 2010; 28:2874-80
Moebus Volker, Konecny Gottfried E, Kreienberg Rolf, Hinke Axel, Runnebaum Ingo B, von Minckwitz Gunter, Harbeck Nadia, Huober Jens, Schneeweiss Andreas, Nitz Ulrike, Kuhn Walther, Kurbacher Christian, Thomssen Christoph, du Bois Andreas, Lueck Hans-Joachim, Jackisch Christian, Untch Michael
Brustzentrum Kantonsspital St. Gallen – von der Multidisziplinarität zur patientinnenzentrierten interdisziplinären Betriebsorganisation
Baumann M, Thürlimann B, Ruhstaller T. Brustzentrum Kantonsspital St. Gallen – von der Multidisziplinarität zur patientinnenzentrierten interdisziplinären Betriebsorganisation. Breast Care 2010; 5:188-191.
Jun 8, 2010Brustzentrum Kantonsspital St. Gallen – von der Multidisziplinarität zur patientinnenzentrierten interdisziplinären Betriebsorganisation
Jun 8, 2010Breast Care 2010; 5:188-191
Baumann Michael, Thürlimann Beat, Ruhstaller Thomas
Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study
Rao S, Beadman C, Kurek R, Archer C, Wilke H, Valladares-Ayerbes M, Ruhstaller T, Gilligan D, Sumpter K, Cunningham D, Starling N, Oates J. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Ann Oncol 2010; 21:2213-9.
May 23, 2010Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study
May 23, 2010Ann Oncol 2010; 21:2213-9
Rao S, Beadman C, Kurek R, Archer C, Wilke H, Valladares-Ayerbes M, Ruhstaller Thomas, Gilligan D, Sumpter K, Cunningham D, Starling N, Oates J
Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer
Hawle H, Hess D, Mueller A, Thürlimann B. Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer. Case Rep Oncol 2010; 3:131-136.
Apr 29, 2010Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer
Apr 29, 2010Case Rep Oncol 2010; 3:131-136
Hawle H, Hess Dagmar, Mueller A, Thürlimann Beat
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial
Riethdorf S, von Minckwitz G, Untch M, Eidtmann H, Tesch H, Holms F, Hilfrich J, Schrader I, Fehm T, Huober J, Roller M, Komor M, Loibl S, Rau T, Zhang L, Müller V, Pantel K. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010; 16:2634-45.
Apr 20, 2010Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial
Apr 20, 2010Clin Cancer Res 2010; 16:2634-45
Riethdorf Sabine, von Minckwitz Gunter, Untch Michael, Eidtmann Holger, Tesch Hans, Holms Frank, Hilfrich Jörn, Schrader Iris, Fehm Tanja, Huober Jens, Roller Marc, Komor Martina, Loibl Sibylle, Rau Thomas, Zhang Liling, Müller Volkmar, Pantel Klaus
Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial
Phillips K, Gelber R, Price K, Goldhirsch A, Coates A, Pagani O, Cardoso F, Thürlimann B, Harvey V, Thompson A, Stephens A, Sun Z, Ribi K, Bernhard J. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. Breast 2010; 19:388-95.
Apr 10, 2010Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial
Apr 10, 2010Breast 2010; 19:388-95
Phillips Kelly-Anne, Gelber Richard D, Price Karen N, Goldhirsch Aron, Coates Alan S, Pagani Olivia, Cardoso Fatima, Thürlimann Beat, Harvey Vernon, Thompson Alastair, Stephens Alisa, Sun Zhuoxin, Ribi Karin, Bernhard Jürg
Bisphosphonates in adjuvant treatment of early breast cancer
The Scientific Board, Harbeck N, von Minckwitz G, Thürlimann B. Bisphosphonates in adjuvant treatment of early breast cancer. Crit Rev Oncol Hematol 2010; 74S1:S1.
Apr 1, 2010Bisphosphonates in adjuvant treatment of early breast cancer
Apr 1, 2010Crit Rev Oncol Hematol 2010; 74S1:S1
The Scientific Board, Harbeck Nadia, von Minckwitz Gunter, Thürlimann Beat
Bone targeted therapy in breast cancer: present and future
Huober J, Thürlimann B. Bone targeted therapy in breast cancer: present and future. Crit Rev Oncol Hematol 2010; 74S1:S7-S10.
Apr 1, 2010Bone targeted therapy in breast cancer: present and future
Apr 1, 2010Crit Rev Oncol Hematol 2010; 74S1:S7-S10
Huober Jens, Thürlimann Beat
[Breast cancer: screening, treatment and follow-up]
Hasler-Strub U, Moos R. [Breast cancer: screening, treatment and follow-up]. Praxis (Bern 1994) 2010; 99:413-8.
Mar 31, 2010[Breast cancer: screening, treatment and follow-up]
Mar 31, 2010Praxis (Bern 1994) 2010; 99:413-8
Hasler-Strub Ursula, Moos R von
Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer
Retèl V, Joore M, Knauer M, Linn S, Hauptmann M, Harten W. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. Eur J Cancer 2010; 46:1382-91.
Mar 30, 2010Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer
Mar 30, 2010Eur J Cancer 2010; 46:1382-91
Retèl Valesca P, Joore Manuela A, Knauer Michael, Linn Sabine C, Hauptmann Michael, Harten Wim H van
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study
von Minckwitz G, Kühn T, du Bois A, Blohmer J, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Hanusch C, Gerber B, Rezai M, Loibl S, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Untch M. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 2010; 28:2015-23.
Mar 22, 2010Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study
Mar 22, 2010J Clin Oncol 2010; 28:2015-23
von Minckwitz Gunter, Kühn Thorsten, du Bois Andreas, Blohmer Jens-Uwe, Thomssen Christoph, Dan Costa Serban, Jackisch Christian, Kaufmann Manfred, Mehta Keyur, Hanusch Claus, Gerber Bernd, Rezai Mahdi, Loibl Sibylle, Fasching Peter A, Huober Jens, Tesch Hans, Bauerfeind Ingo, Hilfrich Jörn, Eidtmann Holger, Untch Michael
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study
Untch M, Kühn T, du Bois A, Blohmer J, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Hanusch C, Gerber B, Rezai M, Loibl S, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, von Minckwitz G. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010; 28:2024-31.
Mar 22, 2010Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study
Mar 22, 2010J Clin Oncol 2010; 28:2024-31
Untch Michael, Kühn Thorsten, du Bois Andreas, Blohmer Jens-Uwe, Thomssen Christoph, Dan Costa Serban, Jackisch Christian, Kaufmann Manfred, Mehta Keyur, Hanusch Claus, Gerber Bernd, Rezai Mahdi, Loibl Sibylle, Fasching Peter A, Huober Jens, Tesch Hans, Bauerfeind Ingo, Hilfrich Jörn, Eidtmann Holger, von Minckwitz Gunter
Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical Cancer Research (SAKK 75/02)
Jost C, Meyenberger C, Brauchli P, Bertschinger P, Frossard J, Knuchel J, Werth B, Metzger U, Bauerfeind P, Schuller J, Binek J, Ruhstaller T. Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical Cancer Research (SAKK 75/02). Gastrointest Endosc 2010; 71:1114-21.
Mar 20, 2010Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical Cancer Research (SAKK 75/02)
Mar 20, 2010Gastrointest Endosc 2010; 71:1114-21
Jost Christian, Meyenberger Christa, Brauchli Peter, Bertschinger Philipp, Frossard Jean-Louis, Knuchel Juerg, Werth Baseli, Metzger Urs, Bauerfeind Peter, Schuller Jan C, Binek Janek, Ruhstaller Thomas
The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer
Knauer M, Linn S, Bueno-de-Mesquita J, Koornstra R, van de Vijver M, Hauptmann M, Bender R, Rutgers E, Mook S, van 't Veer L. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2010; 120:655-61.
Mar 5, 2010The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer
Mar 5, 2010Breast Cancer Res Treat 2010; 120:655-61
Knauer Michael, Linn Sabine C, Bueno-de-Mesquita Jolien M, Koornstra Rutger H T, van de Vijver Marc J, Hauptmann Michael, Bender Richard A, Rutgers Emiel J T, Mook Stella, van 't Veer Laura J
Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer
Paridaens R, Coates A, Crivellari D, Holmberg S, Price K, Thürlimann B, Gelber R, Cole B, Gelber S, Goldhirsch A. Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 2010; 123:303-10.
Feb 27, 2010Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer
Feb 27, 2010Breast Cancer Res Treat 2010; 123:303-10
Paridaens Robert J, Coates Alan S, Crivellari Diana, Holmberg Stig B, Price Karen N, Thürlimann Beat, Gelber Richard D, Cole Bernard F, Gelber Shari, Goldhirsch Aron
Geographic variation in breast cancer care in Switzerland
Ess S, Savidan A, Frick H, Rageth C, Vlastos G, Lütolf U, Thürlimann B. Geographic variation in breast cancer care in Switzerland. Cancer Epidemiol 2010; 34:116-21.
Feb 24, 2010Geographic variation in breast cancer care in Switzerland
Feb 24, 2010Cancer Epidemiol 2010; 34:116-21
Ess S, Savidan A, Frick H, Rageth Ch, Vlastos G, Lütolf U, Thürlimann Beat
Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue
Antonov J, Aebi S, Altermatt H, Viale G, Giobbie-Hurder A, Thürlimann B, Oberli A, Baltzer A, Wirapati P, Delorenzi M, Popovici V, Jaggi R. Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue. BMC cancer 2010; 10:37.
Feb 9, 2010Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue
Feb 9, 2010BMC cancer 2010; 10:37
Antonov Janine, Aebi Stefan, Altermatt Hans Jorg, Viale Giuseppe, Giobbie-Hurder Anita, Thürlimann Beat, Oberli Andrea, Baltzer Anna, Wirapati Pratyaksha, Delorenzi Mauro, Popovici Vlad, Jaggi Rolf
Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer
Huober J, Schoch O, Templeton A, Spirig C, Thürlimann B. Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer. Chemotherapy 2010; 56:69-70.
Feb 8, 2010Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer
Feb 8, 2010Chemotherapy 2010; 56:69-70
Huober Jens, Schoch Otto, Templeton Arnoud, Spirig Christian, Thürlimann Beat